A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

Intra-Cellular Therapies has a 12-month low of $64.09 and a 12-month high of $131.98. The company has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The business had revenue of $199.22 million for the quarter, compared to the consensus ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...

Johnson & Johnson now expects sales of up to $91.8 billion in 2025, compared with a prior view of up to $90 billion.

Learn about drug types, stages, administration routes, and molecular classifications. Explore therapies under development, emerging drugs, and key pl ...

Johnson & Johnson on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full ...

Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will get $132 per share ...

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) ...

As the hiring market surges for Wall Street law firms, Davis Polk’s small mergers and acquisitions practice with a high ...

The Franklin Small Cap Growth Fund underperformed its Russell 2000 Growth Index benchmark in the first quarter of 2025. Click ...

Aspen Neuroscience has released 6-month data from the first three patients dosed in the ASPIRO Phase 1/2a trial of ANPD001, an investigational autologous dopaminergic neuronal precursor cell (DANPC) ...